Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 94.14Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 30.36です。
適正水準
同社の最新のPEは-0.36で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は34.64M株で、前四半期比で16.84%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を1.85M株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.72です。